Today: February 24, 2018, 3:36 am

Herantis Pharma receives Life Sciences Nordic Stars Award 2017-09-15 07:32:02

Herantis Pharma receives Life Sciences Nordic Stars Award

Herantis Pharma Plc
Press release 15 Sep 2017 at 8:30 am

Herantis Pharma plc ("Herantis") received the Nordic Stars Award at the Nordic Life Sciences Days in Malmö, Sweden. Nordic Stars Awards winners have been selected annually since 2013 "in special recognition of life science companies in the Nordic region demonstrating outstanding innovation and entrepreneurial skills." The other winners in 2017 were Targovax (Norway) and Pelago Bioscience (Sweden).

"This award is above all a recognition of the high quality of scientific research in Finland", appreciates Pekka Simula, Herantis' CEO. "Our drug candidate Lymfactin® is based on the scientific research by professor Kari Alitalo's group, and our drug candidate CDNF is based on the research by professor Mart Saarma's group. Both are examples of ground-breaking medical research in Finland representing globally leading science. This recognition also reminds of the opportunities that high-quality science will open in the future for Finland, our nation now celebrating 100 years of independence."

Further information:

Herantis Pharma plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site:

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine for breakthrough in unmet clinical needs. Our first-in-class assets are based on globally leading scientific research in their fields: CDNF for disease modification in neurodegenerative diseases, primarily Parkinson's and ALS; and Lymfactin® for breast cancer associated lymphedema, with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.

About CDNF

CDNF is a novel drug candidate for the treatment of neurodegenerative diseases. Naturally present in the human blood circulation and cerebrospinal fluid, CDNF is a protein with neuroprotective and neurorestorative properties, patented worldwide by Herantis.  Encouraged by strong preclinical proof-of-concept Herantis has launched a first-in-human, randomized Phase 1-2 clinical study with CDNF for the treatment of Parkinson's disease. The clinical study has received funding from the European Union's research and innovation program Horizon 2020 under grant agreement number 732386.

CDNF administration has been safe in preclinical studies including chronic toxicology studies; CDNF has protected and regenerated midbrain dopamine-generating cells suggesting potential for disease modification of PD. It has also shown efficacy in non-motor symptoms of PD. In an ALS disease model CDNF has significantly increased survival and reduced symptoms. This suggests the potential to address unmet clinical needs in both PD and ALS. CDNF drug development is based on scientific research at the University of Helsinki, lead by professor Mart Saarma.

About Lymfactin®

Lymfactin® is the world's first clinical stage gene therapy repairing damages of the lymphatic system. Lymfactin® expresses the growth factor VEGF-C, which is specific to the development of lymphatic vessels. Based on preclinical studies Lymfactin® triggers the growth of new functional lymphatic vasculature and thus repairs the damages causing secondary lymphedema. Encouraged by preclinical results Herantis has launched a Phase 1 clinical study with Lymfactin® in the treatment of breast cancer associated lymphedema. Patented by Herantis, Lymfactin® is based on scientific research by academy professor Kari Alitalo and his research group, a national centre of excellence at the University of Helsinki. See our introductory video on Lymfactin®:


Main media

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Herantis Pharma Oyj via Globenewswire

# 779 Words
Related Articles
More From The Author
CrowdStrike Expands Operations and Leadership Team in [..]
CrowdStrike® Inc., the leader in cloud-delivered endpoint protection, today announced the further expansion of its operations in [..]
A.M. Best Affirms Credit Ratings of Active [..]
A.M. Best has affirmed the Financial Strength Rating (FSR) of B++ (Good) and the Long-Term Issuer Credit Rating (Long-Term ICR) [..]
A.M. Best Assigns Credit Ratings to Seguros [..]
A.M. Best has assigned a Financial Strength Rating of A- (Excellent) and a Long-Term Issuer Credit Rating of “a-” to [..]
Independent Data Monitoring Committee Recommends Discontinuation of [..]
Conference call scheduled for 2:00 PM CEST / 8:00 AM EDT tomorrow, Friday, September 15 COPENHAGEN, Denmark, September 14, 2017 [..]
A.M. Best Removes From Under Review With [..]
A.M. Best has removed from under review with negative implications and downgraded the Financial Strength Rating to a Non-Rating Designation [..]
More From Business
The Advantages of Cleaning With Steam With [..]
The secret of steam cleaning lies in the powerful combination of pressure, speed and temperature, as microscopic steam particles force [..]
Bright Light Stocks Full Range of Constant [..]
Bright Light has constant voltage power supplies that will allow LEDs to work efficiently and safely. These power sources are [..]
Buy Olympic Bars for Powerlifting, Weightlifting & [..]
Established in 1942, the Australian Barbell Company is Australia’s leading specialist manufacturer and supplier of weight lifting [..]
Buyers Agency Albion Avenue Has Great Options [..]
Real estate experts say the property market in Sydney and Melbourne peaked in 2017 and judging by recent auction and [..]
The Secret of Truedek’s Strength
An article in a business magazine in the 1970’s gave an example of the difference between Government and Private Enterprise. [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.